- Trials with a EudraCT protocol (35)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
35 result(s) found for: Drug-withdrawal..
Displaying page 1 of 2.
EudraCT Number: 2015-001043-37 | Sponsor Protocol Number: LORA01 | Start Date*: 2015-06-30 | |||||||||||
Sponsor Name:Erasmus MC | |||||||||||||
Full Title: Pharmacokinetics of Lorazepam Oral Liquid in Paediatric ICU Patients | |||||||||||||
Medical condition: Withdrawal | |||||||||||||
|
|||||||||||||
Population Age: Newborns, Infants and toddlers, Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-000630-22 | Sponsor Protocol Number: TV50717-CNS-30047 | Start Date*: 2018-06-05 |
Sponsor Name:Teva Branded Pharmaceutical Products R&D, Inc. | ||
Full Title: An Open-Label, Long-Term Safety Study Including a Double-Blind, Placebo-Controlled, Randomized Withdrawal Period of TEV-50717 (deutetrabenazine) for the Treatment of Tourette Syndrome in Children a... | ||
Medical condition: Tics associated with Tourette Syndrome(TS) | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: HU (Completed) SE (Prematurely Ended) ES (Prematurely Ended) DK (Prematurely Ended) PL (Completed) FR (Completed) NL (Ongoing) IT (Prematurely Ended) RO (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2020-000107-36 | Sponsor Protocol Number: VER-CLBP-001 | Start Date*: 2021-03-24 |
Sponsor Name:Vertanical GmbH | ||
Full Title: Proof of efficacy, maintenance of efficacy, long-term safety and investigation of the potential for dependence and abuse and the effect of abrupt drug withdrawal of VER-01 in a multicenter study in... | ||
Medical condition: For the treatment of patients with chronic non-specific low back pain when drug treatment is indicated and previous optimised treatments with non-opioid analgesics have not led to sufficient pain r... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) AT (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2007-006773-92 | Sponsor Protocol Number: FARM6TT8SP | Start Date*: 2008-07-23 | ||||||||||||||||
Sponsor Name:UNIVERSITA' DEGLI STUDI DI PERUGIA | ||||||||||||||||||
Full Title: Sodium Valproate in the treatment of medication overuse headache: a controlled randomized clinical trial. | ||||||||||||||||||
Medical condition: medication overuse headache | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: IT (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-005971-18 | Sponsor Protocol Number: 13-617 | Start Date*: 2014-01-24 |
Sponsor Name:University Medical Center Utrecht | ||
Full Title: TimeToStop (TTS) Trial, A randomised controlled trial of early versus late antiepileptic drug withdrawal after pediatric epilepsy surgery | ||
Medical condition: We will investigate possible cognitive benifits of early antiepileptic drug withdrawal after pediatric epilepsy surgery. The concerning medical condition is refractory epilepsy | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: NL (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2005-003442-33 | Sponsor Protocol Number: D8480C00038 | Start Date*: 2005-11-22 |
Sponsor Name:AstraZeneca AB | ||
Full Title: A Phase II, Randomised, Factorial, Double-blind Study to Investigate the Management of AZD2171-induced Hypertension and Efficacy of AZD2171 at Doses of 30 mg and 45 mg in Patients with Advanced Sol... | ||
Medical condition: Management of AZD2171-induced hypertension in patients with advanced solid tumours | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2019-003888-22 | Sponsor Protocol Number: MEF-HF-2020-01 | Start Date*: 2020-11-17 |
Sponsor Name:University of Zagreb School of Medicine | ||
Full Title: A multicENter, randomized, open-label, parallel group, pilot study to evaluate the use of sacubitril/valsartan in HeartMate 3 LVAD recipients | ||
Medical condition: Heart failure Heart failure with reduced ejection fraction Advanced Heart failure | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: HR (Ongoing) NL (Completed) PL (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2006-005630-21 | Sponsor Protocol Number: RG_06-180 | Start Date*: 2009-04-09 |
Sponsor Name:University of Birmingham
[...]
1. University of Birmingham
2. Birmingham Heartlands Hospital |
||
Full Title: The effect of Pregabalin on Pain progressing in Painful Diabetic Neuropathy | ||
Medical condition: Diabtes and its complications, painful neuropathy | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2011-000719-19 | Sponsor Protocol Number: 09/100/10 | Start Date*: 2011-05-05 |
Sponsor Name:University of Birmingham | ||
Full Title: A Randomised Controlled Trial of the Efficacy and Mechanism of Levothyroxine Treatment on Pregnancy and Neonatal Outcomes in Women with Thyroid Antibodies. (TABLET: Thyroid AntiBodies and LEvoThyro... | ||
Medical condition: Thyroid autoimmunity and history of miscarriage or infertility. | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults | Gender: Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2008-002185-60 | Sponsor Protocol Number: SUB9001 | Start Date*: 2009-07-09 | |||||||||||||||||||||||||||||||||||||||||
Sponsor Name:Mundipharma Medical Company, Basel | |||||||||||||||||||||||||||||||||||||||||||
Full Title: RANDOMISED, CONTROLLED CLINICAL STUDY REGARDING THE FEASIBILITY OF CONVERTING OPIATE DEPENDENTS FROM METHADONE SUBSTITUTES TO SLOW RELEASE MORPHINE SULPHATE (SEVRE-LONG®) | |||||||||||||||||||||||||||||||||||||||||||
Medical condition: Patients with an opioid or multiple substance dependence (including opioids), actually enrolled in a methadone maintenance therapy in one of the study centres (ICD classifications F11.22, F19.22). | |||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||||||||||||
Trial protocol: DE (Completed) | |||||||||||||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2020-002803-20 | Sponsor Protocol Number: APPI2-2020-AD03 | Start Date*: 2020-11-06 | |||||||||||
Sponsor Name:Parker Instituttet | |||||||||||||
Full Title: Colchicine treatment for patients with hand osteoarthritis: A randomised, placebo-controlled trial | |||||||||||||
Medical condition: Hand osteoarthritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-005102-38 | Sponsor Protocol Number: 1311.4 | Start Date*: 2016-04-14 | |||||||||||
Sponsor Name:Boehringer Ingelheim Pharma GmbH & Co. KG | |||||||||||||
Full Title: BI 655066 / ABBV-066 (risankizumab) versus placebo In a Multicenter randomized double-blind study in patients with Moderate to severe chronic plaque psoriasis evaluating the efficacy and safety ... | |||||||||||||
Medical condition: | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) BE (Completed) CZ (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-000436-28 | Sponsor Protocol Number: Z102-008 | Start Date*: 2011-12-07 | |||||||||||
Sponsor Name:Zalicus, Inc. | |||||||||||||
Full Title: A PHASE II, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTI-CENTER, RANDOMIZED WITHDRAWAL DESIGN TRIAL USING ADAPTIVE RANDOMIZATION COMPARING Z102 WITH PLACEBO IN PATIENTS WITH MODERATE TO SEVERE RHEUMATOI... | |||||||||||||
Medical condition: Treatment of patients with moderate to severe rheumatoid arthritis (RA) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Completed) HU (Completed) BG (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-000300-42 | Sponsor Protocol Number: 03AR0298 | Start Date*: 2013-01-18 |
Sponsor Name:National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | ||
Full Title: A long-term outcome study with the IL-1 receptor antagonist Anakinra/Kineret® in patients with Neonatal onset multisystem inflammatory disease (Nomid/Cinca syndrome) | ||
Medical condition: neonatal onset multisystem inflammatory disease (NOMID/CINCA) | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2020-001045-39 | Sponsor Protocol Number: CT-P43_3.1 | Start Date*: 2020-11-12 | |||||||||||
Sponsor Name:Celltrion, Inc | |||||||||||||
Full Title: A Randomized, Active-Controlled, Double-Blind, Phase 3 Study to Compare the Efficacy and Safety of CT-P43 to Stelara in Patients with Moderate to Severe Plaque Psoriasis | |||||||||||||
Medical condition: Moderate to Severe Plaque Psoriasis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: EE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2022-002336-31 | Sponsor Protocol Number: CT-P17-3.3 | Start Date*: 2022-10-20 | |||||||||||
Sponsor Name:CELLTRION, Inc | |||||||||||||
Full Title: A Randomized, Active-Controlled, Double-Blind, Phase 3 Study to Compare Pharmacokinetics, Efficacy, and Safety of CT-P17 with Humira in Patients with Moderate to Severe Chronic Plaque Psoriasis | |||||||||||||
Medical condition: Moderate to Severe Chronic Plaque Psoriasis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: EE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-001147-24 | Sponsor Protocol Number: ONC-2021-001 | Start Date*: 2023-04-12 | |||||||||||
Sponsor Name:IRCCS ISTITUTO CLINICO HUMANITAS | |||||||||||||
Full Title: Use of LOncastuximab Tesirine in patients with RElapsed/Refractory Diffuse Large B-Cell LYmphoma (DLBCL) or High Grade B-Cell Lymphoma (HGBCL) who have progressive disease after CAR T-cell treatmen... | |||||||||||||
Medical condition: Patients affected by relapsed/refractory DLBCL or HGBCL failing CAR T-cell therapy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-000952-36 | Sponsor Protocol Number: CT-P39_3.1 | Start Date*: 2021-02-05 | |||||||||||
Sponsor Name:CELLTRION, Inc. | |||||||||||||
Full Title: A Double-blind, Randomized, Active-controlled, Parallel Group, Phase 3 Study to Compare Efficacy and Safety of CT-P39 and Xolair in Patients With Chronic Spontaneous Urticaria Who Remain Symptomati... | |||||||||||||
Medical condition: Chronic Spontaneous Urticaria | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) PL (Completed) BG (Completed) GR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-004278-23 | Sponsor Protocol Number: CT-P42_3.1 | Start Date*: 2021-03-16 | |||||||||||
Sponsor Name:CELLTRION Inc. | |||||||||||||
Full Title: A Randomized, Active-Controlled, Double-Masked, Parallel-Group, Phase 3 Study to Compare Efficacy and Safety of CT-P42 in Comparison with Eylea in Patients with Diabetic Macular Edema | |||||||||||||
Medical condition: Diabetic Macular Edema | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) SK (Completed) HU (Completed) CZ (Completed) PL (Completed) LT (Completed) LV (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-003859-11 | Sponsor Protocol Number: MO41552 | Start Date*: 2022-02-03 | |||||||||||
Sponsor Name:F.Hoffmann-La Roche Ltd | |||||||||||||
Full Title: RANDOMIZED, OPEN LABEL, MULTICENTER, PHASE III STUDY OF ENTRECTINIB VERSUS CRIZOTINIB IN PATIENTS WITH LOCALLYADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER HARBORING ROS1 GENE REARRANGEMENTS WI... | |||||||||||||
Medical condition: Non-small cell lung cancer with ROS proto-oncogene 1, receptor tyrosine kinase (ROS1) gene rearrangements | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Trial now transitioned) DE (Trial now transitioned) GR (Trial now transitioned) ES (Ongoing) NL (Trial now transitioned) SK (Trial now transitioned) IT (Trial now transitioned) FR (Trial now transitioned) HR (Trial now transitioned) RO (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
• EEA CTAs: Date study was authorised to proceed
• Outside EU/EEA: Date study was submitted in EudraCT
• Outside EU/EEA: Date study was submitted in EudraCT
